GenerexBiotechnology @GenerexBiotech · 11m
Post# of 36537
GenerexBiotechnology
@GenerexBiotech
·
11m
We are currently in ex-Vivo human studies for an Ii-Key #SARSCoV2vaccine using predictive algorithms and our proprietary Ii-Key technology platform to provide safe and long-lasting immunity from #COVID19. To learn more about this technology, visit http://Nugenerexio.com.
Came from the hub board.